Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy
Open Access
- 30 September 2026
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (10) , 996-1014
Abstract
Interleukin‐12 (IL‐12) is a key immunoregulatory cytokine produced primarily by antigen‐presenting cells. During infection, IL‐12 orchestrates innate immune responses and shapes the nature of subsequent adaptive immunity. Specifically, by promoting interferon‐γ (IFN‐γ) production in helper and cytolytic T cells and natural killer (NK) cells, it promotes the activation of these cells and drives the differentiation of CD4 + T cells into type 1 T helper (Th1) cells. IL‐12 is a heterodimeric cytokine composed of the p35 and p40 subunits, whose coordinated expression is required for formation of the bioactive p70 molecule. The promiscuous use of these subunits within the IL‐12 cytokine family, where p40 and p35 also pair with other partners to form IL‐23, IL‐27, and IL‐35, creates structural and functional overlap that enables fine‐tuned immune regulation. Given its potent immune functions, it is not surprising that IL‐12 availability is regulated at multiple levels, including gene transcription, subunit assembly, and shared receptor signaling components. In this review, we provide an overview of IL‐12, how it is produced and secreted and its mechanisms of action. We also discuss the targeting of IL‐12 for the treatment of various diseases, including bacterial infections, autoimmune diseases, and cancer.Keywords
This publication has 118 references indexed in Scilit:
- Augmentation of Solid Tumor Immunotherapy With IL‐12The Journal of Gene Medicine, 2024
- Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer ImmunotherapyAdvanced Materials, 2024
- Leishmania donovani infection differentially regulates small G‐proteinsJournal of Cellular Biochemistry, 2018
- Essential Role of IL-12 in Angiogenesis in Type 2 DiabetesThe American Journal of Pathology, 2017
- Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritisArthritis & Rheumatism, 2011
- Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseInflammatory Bowel Diseases, 2009
- Human microglial cells express a functional IL-12 receptor and produce IL-12 following IL-12 stimulationEuropean Journal of Immunology, 2001
- Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetesEuropean Journal of Immunology, 1997
- Structure and chromosomal location of the mouse interleukin‐12 p35 and p40 subunit genesEuropean Journal of Immunology, 1996
- Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic miceDiabetologia, 1996